British Journal of Cancer

Article	Citations
Role of epigenetics in paediatric cancer pathogenesis & drug resistance	278
Patterns of incident Burkitt lymphoma during the HIV epidemic among the Black African and White population in South Africa	140
Associations between obesity, metabolic health, and the risk of breast cancer in East Asian women	136
Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy	127
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10	123
Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma	122
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	120
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer	120
Tenascin-C expression in the lymph node pre-metastatic niche in muscle-invasive bladder cancer	116
A novel circulating miRNA panel for non-invasive ovarian cancer diagnosis and prognosis	113
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	112
CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer	106
Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium	95
CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer	95
Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy	94
Optimising treatment pathways for borderline and locally advanced pancreatic cancer: an adaptive personalised approach	87
Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial	87
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	85
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer	85
Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC)	84
REMARK guidelines for tumour biomarker study reporting: a remarkable history	84
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	81
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	81
Targeting obesity-related dysfunction in hormonally driven cancers	79
Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma	78

Treating tobacco dependency in cancer care: essential, cost-effective, and feasible, yet overlooked	77
Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells	76
RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC	74
The mental health impacts of receiving a breast cancer diagnosis: A meta-analysis	72
Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank	69
Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients	69
Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia	68
Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis	68
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade	68
The tumour immune microenvironment in oesophageal cancer	68
A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer	67
Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy	66
TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer	65
Socio-economic inequalities in cancer survival: how do they translate into Number of Life-Years Lost?	65
Long-term exposure to ambient air pollution and bladder cancer incidence in a pooled European cohort: the ELAPSE project	65
CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer	63
The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care	62
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts	62
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression	61
Chronic oxidative stress adaptation in head and neck cancer cells generates slow-cyclers with decreased tumour growth in vivo	60
An emerging role for BAG3 in gynaecological malignancies	60
Statin use and survival among women with ovarian cancer: an Australian national data-linkage study	59
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression	59
Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database	57
Pharmacokinetic–pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies	56
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	56
Correction: Maternal and childhood medical history and the risk of childhood brain tumours: a case–control study in Ontario, Canada	56
Liquid biopsy: creating opportunities in brain space	56
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	55
Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases	52
Tertiary lymphoid structures correlate with enhancement of antitumor immunity in esophageal squamous cell carcinoma	51
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	51
A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study	51
Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy	51
Correction: How do women experience a false-positive test result from breast screening? A systematic review and thematic synthesis of qualitative studies	50
Evaluation of tumour infiltrating lymphocytes in luminal breast cancer using artificial intelligence	49
Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80	49
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	48
A taxonomy of early diagnosis research to guide study design and funding prioritisation	48
A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer	48
Significant decrease in interval colorectal cancer incidence after implementing immunochemical testing in a multiple-round guaiac-based screening programme	47
Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer	47
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours	47
Quantitative breast density analysis to predict interval and node-positive cancers in pursuit of improved screening protocols: a case–control study	47
The cost-effectiveness of risk-stratified breast cancer screening in the UK	47
SIRT1 is an actionable target to restore p53 function in HPV-associated cancer therapy	47
Correction to: Timeliness of diagnosis and treatment: the challenge of childhood cancers	46
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma	46
Minimum latency effects for cancer associated with exposures to radiation or other carcinogens	45
Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label,	45

Circulating small extracellular vesicle-based miRNA classifier for follicular thyroid carcinoma: a diagnostic study	45
CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles	44
The use of biomarkers and HPV genotyping to improve diagnostic accuracy in women with a transformation zone type 3	44
Association between weight cycling and risk of colorectal cancer: a prospective cohort study	43
TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors	43
Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas	43
Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy	43
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer	42
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours	42
Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis	41
The HOXB13 variant X285K is associated with clinical significance and early age at diagnosis in African American prostate cancer patients	41
Risk of subsequent gliomas and meningiomas among 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	41
Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients	41
Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test	40
Solar ultraviolet radiation exposure, and incidence of childhood acute lymphocytic leukaemia and non-Hodgkin lymphoma in a US population-based dataset	40
Adenoma characteristics associated with post-polypectomy proximal colon cancer incidence: a retrospective cohort study	40
wMKL: multi-omics data integration enables novel cancer subtype identification via weight-boosted multi-kernel learning	39
Transcriptome analysis reveals upregulation of immune response pathways at the invasive tumour front of metastatic seminoma germ cell tumours	39
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours	39
Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation	38
Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery	38
Association between C-reactive protein and risk of overall and 18 site-specific cancers in a Japanese case-cohort	38
The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity	38
Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity	38
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	38
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer	38
Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis	38
Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma	37
Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab	37
A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp	37
Morpholino-driven blockade of Dkk-1 in osteosarcoma inhibits bone damage and tumour expansion by multiple mechanisms	36
Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence	36
Comments on “Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer”	36
Intratumoural haematopoietic stem and progenitor cell differentiation into M2 macrophages facilitates the regrowth of solid tumours after radiation therapy	36
Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients	36
A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation a	36
Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer	36
RE: Reply to Rio-Vilariño and colleagues’ article and misconception about YAP1 Ser 397 phosphorylation function	36
Correction: Systemic inflammation scores correlate with survival prognosis in patients with newly diagnosed brain metastases	35
Family history, obesity, urological factors and diabetic medications and their associations with risk of prostate cancer diagnosis in a large prospective study	35
A genome-wide association study of radiotherapy induced toxicity in head and neck cancer patients identifies a susceptibility locus associated with mucositis	35
The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa)	34
Anti-PEc: Development of a novel monoclonal antibody against prostate cancer	34
Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer: evidence from population-based prospective cohorts and Mendelian randomisation	34
Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging	34
Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines	33
Impact of germline mutations in cancer-predisposing genes on long-term survival in patients with epithelial ovarian cancer	33
SBSN drives bladder cancer metastasis via EGFR/SRC/STAT3 signalling	33
Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression	33
Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade	33
PFKFB3 works on the FAK-STAT3-SOX2 axis to regulate the stemness in MPM	32
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	32
Potential role of the CD39-CD73 ATP-adenosine pathway in platelet mediated dissemination of circulating tumour cells	32
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	32
Biomarker testing in cancer management- can one size fit all?	31
Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour	31
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	31
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing	31
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	31
Predicted leukocyte telomere length and risk of germ cell tumours	31
What kind of tumour rupture requires adjuvant therapy?	31
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	31
Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study	31
Use the term “infiltrative” instead of “replacement” when defining histopathological growth pattern in patients with liver cancer	30
Alternative methods to measure breast density in younger women	30
Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens	30
Randomised controlled trial of breast cancer and multiple disease prevention weight loss programmes vs written advice amongst women attending a breast cancer family history clinic	30
Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma	30
The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome	30
Increased cross-presentation by dendritic cells and enhanced anti-tumour therapy using the Arp2/3 inhibitor CK666	30
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	30
Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	30
Correction: Height and breast cancer risk in premenopausal Korean women aged under 40 years of age	29
Targeting epidermal growth factor receptor in paclitaxel-resistant human breast and lung cancer cells with upregulated glucose-6-phosphate dehydrogenase	29
Patient attrition in Molecular Tumour Boards: a systematic review	29
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	29
Revitalising cancer clinical trials: definitely time for patient-centred reform	29
The dark side of synaptic proteins in tumours	29
Circulating tumour cells in gastrointestinal cancers: food for thought?	29
Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer	29

Crucial immunological roles of the invasion front in innate and adaptive immunity in cervical cancer	29
Author Correction: CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer	29
Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer	28
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	28
Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis	28
Correction: Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer	28
Temporal dynamics of immune cell patterns in bladder cancer patients receiving Bacillus Calmette-Guérin therapy	28
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306	28
BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial	28
HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial	28
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	28
Author Correction: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus	28
Mammography radiomics features at diagnosis and progression-free survival among patients with breast cancer	27
Cancer care for migrant people	27
Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Co	27
Advancing radiomics from contrast-enhanced mammography in breast cancer	27
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	27
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	27
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	27
The role of PPARγ in prostate cancer development and progression	27
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	27
Non-B DNA-informed mutation burden as a marker of treatment response and outcome in cancer	27
Tumor budding and lymphovascular invasion as prognostic factors in p16-positive oropharyngeal squamous cell carcinomas	27
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma	27
Cancer survivorship and risk of pregnancy complications, adverse obstetric outcomes, and maternal morbidities in female adolescents and young adults: a nationwide population-based study from Taiwan	26
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial	26
Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study	26
CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer	26
Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy	26
Whole-exome and targeted gene sequencing of large-cell lung carcinoma reveals recurrent mutations in the PI3K pathway	26
Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom	26
MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness	26
Deep learning-based pathology signature could reveal lymph node status and act as a novel prognostic marker across multiple cancer types	26
Associations of diabetes, circulating protein biomarkers, and risk of pancreatic cancer	26
Publisher Correction	26
Consumption of olive oil and risk of breast cancer in U.S. women: results from the Nurses’ Health Studies	26
Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology	26
Prognostic benefit of TILs independent of clinicopathological and molecular factors	26
Correction to: Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort	26
Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges	26
Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases	26
ACE inhibitors and the risk of lung cancer—is there causality?	26
Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents	26
Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients	26
Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression	26
Correction: IQGAP1 promotes anoikis resistance and metastasis through Rac1-dependent ROS accumulation and activation of Src/FAK signalling in hepatocellular carcinoma	25
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies	25
Standardised survival probabilities: a useful and informative tool for reporting regression models for survival data	25
Correction to: Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma	25
Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment	25
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma	25
Advancing translational research for colorectal immuno-oncology	25
Clinical and genomic correlates of imatinib response in melanomas with KIT alterations	25
Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules	24
Cancer-specific tissue-resident memory T-cells express ZNF683 in colorectal cancer	24
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients	24
Risk of cancer following primary care presentation with fatigue: a population-based cohort study of a quarter of a million patients	24
MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer	24
Adherence to the Danish food-based dietary guidelines and risk of colorectal cancer: a cohort study	24
The NHS England 100,000 Genomes Project: feasibility and utility of centralised genome sequencing for children with cancer	24
Vascular normalisation as the stepping stone into tumour microenvironment transformation	24
AIP: A double agent? The tissue-specific role of AIP as a tumour suppressor or as an oncogene	24
Metastasis-associated fibroblasts in peritoneal surface malignancies	24
Associations between circulating proteins and risk of breast cancer by intrinsic subtypes: a Mendelian randomisation analysis	24
Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer	24
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them	24
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma	24
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis	24
Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling	24
The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer	23
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit	23
GDP-bound Rab37 modulates M2-like tumor-associated macrophage polarization by attenuating STAT1 translocation to downregulate the type I IFN pathway	23
An old friend with a new face: tRNA-derived small RNAs with big regulatory potential in cancer biology	23
Dietary intake of total, heme and non-heme iron and the risk of colorectal cancer in a European prospective cohort study	23
Th2 cells inhibit growth of colon and pancreas cancers by promoting anti-tumorigenic responses from macrophages and eosinophils	23
TGFβ carrying exosomes in plasma: potential biomarkers of cancer progression in patients with head and neck squamous cell carcinoma	23
Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy	23
Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours	23
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience	23
Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against	22
Comment on “Redefining cancer research for therapeutic breakthroughs”	22
Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom	22
Ultrasound-targeted microbubble destruction remodels tumour microenvironment to improve immunotherapeutic effect	22
CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer	22
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours	22
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours	22
Pretreatment tumour immune microenvironment predicts clinical response and prognosis of muscle-invasive bladder cancer in the neoadjuvant chemotherapy setting	22
Genomic ALK alterations in primary and relapsed neuroblastoma	22
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3	22
KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer	22
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	22
PI-RADSAI: introducing a new human-in-the-loop AI model for prostate cancer diagnosis based on MRI	22
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours	22
Blockade of TGF-β and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses	22
Immuno-genomic characterisation of high-grade serous ovarian cancer reveals immune evasion mechanisms and identifies an immunological subtype with a favourable prognosis and improved therapeutic effic	22